Payment overview · 2025
General Payments
$2,864.52
142 reported records · 25 companies
Healthcare provider profile · identity verified
Jill D Felder, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · STEUBENVILLE, OH · NPI 1801871587
Verified facts
What the public records show
CMS Open Payments records show Jill D Felder, MD received $2,864.52 in general payments during 2025 across 142 reported records.
RECORDATI_RARE_DISEASES_INC. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Isturisa, Jardiance, Korlym, Mounjaro, Ozempic, Rybelsus, Unithroid.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Unithroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 694 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 694 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 848 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Rybelsus by this doctor in 2024.
RECORDATI_RARE_DISEASES_INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISTURISA as an associated drug or biological on 7831 records involving 3061 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Isturisa by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $409.48 | 14.3% | 19 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $358.26 | 12.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $334.54 | 11.7% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $330.27 | 11.5% | 19 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $201.65 | 7.0% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $200.83 | 7.0% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $123.64 | 4.3% | 6 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $121.13 | 4.2% | 9 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $107.71 | 3.8% | 5 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $93.05 | 3.2% | 5 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $78.10 | 2.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $74.01 | 2.6% | 3 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $61.68 | 2.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.70 | 2.1% | 4 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $58.50 | 2.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $48.63 | 1.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.35 | 1.6% | 3 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $25.00 | 0.9% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $23.84 | 0.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.43 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.70 | 0.7% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $18.33 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.44 | 0.6% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.43 | 0.6% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.82 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,864.52 | 142 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $409.48 | 19 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $287.38 | 10 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $201.65 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.83 | 13 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $198.84 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $180.42 | 9 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $159.42 | 13 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $121.13 | 9 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $121.13 | 9 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $121.13 | 9 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $107.71 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $103.22 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $99.97 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $93.05 | 5 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $78.10 | 2 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $74.01 | 3 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $61.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.13 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $48.63 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $46.63 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.03 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ISTURISA isturisa |
2025 | Isturisa | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 694 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 355 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 848 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 111 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
694 | 128 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
694 | 128 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
355 | 76 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
280 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
848 | 159 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| RECORDATI_RARE_DISEASES_INC. Exact reporting entity; no affiliate inference |
2025 | ISTURISA open payments reported associated product |
CMS Open Payments — General Payments 7831 supporting records · 3061 recipient NPIs · example record 1181711288 |
Isturisa · 2024 Exact normalized brand match · 1 Part D row |
159 | 30 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1155 | 285 |
| Ozempic | Semaglutide | 848 | 159 |
| Glimepiride | Glimepiride | 775 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 178 |
| Jardiance | Empagliflozin | 694 | 128 |
| Metformin Hcl | Metformin Hcl | 612 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 570 | 136 |
| Mounjaro | Tirzepatide | 355 | 76 |
| Metformin Hcl Er | Metformin Hcl | 286 | 75 |
| Trulicity | Dulaglutide | 280 | 61 |
| Ezetimibe | Ezetimibe | 276 | 76 |
| Fenofibrate | Fenofibrate Nanocrystallized | 269 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 243 | 85 |
| Farxiga | Dapagliflozin Propanediol | 171 | 42 |
| Glipizide | Glipizide | 166 | 47 |
| Terbinafine Hcl | Terbinafine Hcl | 166 | 40 |
| Methimazole | Methimazole | 163 | 40 |
| Isturisa | Osilodrostat Phosphate | 159 | 30 |
| Alendronate Sodium | Alendronate Sodium | 132 | 38 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 130 | 39 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 124 | 30 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 120 | 28 |
| Rybelsus | Semaglutide | 111 | 29 |
| Novolog Flexpen | Insulin Aspart | 109 | 46 |
| Tresiba Flextouch U-200 | Insulin Degludec | 107 | 33 |
| Simvastatin | Simvastatin | 104 | 22 |
| Potassium Chloride | Potassium Chloride | 102 | 31 |
| Dexamethasone | Dexamethasone | 100 | 81 |
| Synthroid | Levothyroxine Sodium | 100 | 31 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 100 | 39 |
| Allopurinol | Allopurinol | 98 | 25 |
| Fenofibrate | Fenofibrate | 95 | 23 |
| Spironolactone | Spironolactone | 95 | 26 |
| Acarbose | Acarbose | 92 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 83 | 35 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 22 |
| Liothyronine Sodium | Liothyronine Sodium | 80 | 26 |
| Unithroid | Levothyroxine Sodium | 80 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 78 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 26 |
| Repaglinide | Repaglinide | 77 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 72 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 20 |
| Glipizide Er | Glipizide | 64 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | 22 |
| Armour Thyroid | Thyroid,pork | 60 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 59 | 13 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 57 | 19 |
| Calcitriol | Calcitriol | 56 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 56 | 26 |
| Hydrocortisone | Hydrocortisone | 56 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 55 | 18 |
| Repatha Sureclick | Evolocumab | 54 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 49 | 18 |
| Lisinopril | Lisinopril | 48 | 15 |
| Anastrozole | Anastrozole | 47 | suppressed |
| Vascepa | Icosapent Ethyl | 46 | 14 |
| Repatha Syringe | Evolocumab | 45 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 44 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 44 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 12 |
| Victoza 3-Pak | Liraglutide | 40 | 12 |
| Atenolol | Atenolol | 39 | 11 |
| Fluconazole | Fluconazole | 39 | 13 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 37 | 18 |
| Losartan Potassium | Losartan Potassium | 37 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Gabapentin | Gabapentin | 33 | 13 |
| Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 12 |
| Insulin Lispro | Insulin Lispro | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Testosterone | Testosterone | 27 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | 14 |
| Novofine 32 | Pen Needle, Diabetic | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 19 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 17 | suppressed |
| Korlym | Mifepristone | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Omeprazole | Omeprazole | 15 | suppressed |
| Propylthiouracil | Propylthiouracil | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,864.52 · 142 records | RECORDATI_RARE_DISEASES_INC. | CRENESSITY, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NP Thyroid 60, Ozempic, PROCLAIM, PROLIA, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, STRENSIQ, TEPEZZA, TERIPARATIDE, TWIIST, TZIELD, Tlando, UNITHROID, Wegovy, XYOSTED, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Isturisa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error